Novavax Future Growth
Future criteria checks 3/6
Novavax's revenue is forecast to decline at 14.6% per annum while its annual earnings are expected to grow at 69.4% per year. EPS is expected to grow by 71% per annum.
Key information
69.4%
Earnings growth rate
71.0%
EPS growth rate
| Biotechs earnings growth | 35.0% |
| Revenue growth rate | -14.6% |
| Future return on equity | n/a |
| Analyst coverage | Low |
| Last updated | 16 Oct 2024 |
Recent future growth updates
Recent updates
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 646 | 145 | 117 | 388 | 4 |
| 12/31/2025 | 546 | -26 | 77 | -66 | 5 |
| 12/31/2024 | 761 | -128 | -124 | 26 | 5 |
| 6/30/2024 | 988 | -294 | -24 | 14 | N/A |
| 3/31/2024 | 997 | -399 | -514 | -472 | N/A |
| 12/31/2023 | 984 | -545 | -773 | -714 | N/A |
| 9/30/2023 | 1,050 | -549 | -727 | -655 | N/A |
| 6/30/2023 | 1,597 | -587 | -737 | -654 | N/A |
| 3/31/2023 | 1,359 | -1,155 | -753 | -653 | N/A |
| 12/31/2022 | 1,982 | -658 | -509 | -416 | N/A |
| 9/30/2022 | 1,847 | -1,322 | -728 | -641 | N/A |
| 6/30/2022 | 1,291 | -1,476 | -814 | -744 | N/A |
| 3/31/2022 | 1,403 | -1,318 | -489 | -429 | N/A |
| 12/31/2021 | 1,146 | -1,744 | 265 | 323 | N/A |
| 9/30/2021 | 1,204 | -1,075 | 454 | 537 | N/A |
| 6/30/2021 | 1,182 | -950 | 593 | 672 | N/A |
| 3/31/2021 | 919 | -615 | 575 | 644 | N/A |
| 12/31/2020 | 476 | -418 | -97 | -43 | N/A |
| 9/30/2020 | 205 | -273 | 49 | 62 | N/A |
| 6/30/2020 | 50 | -93 | 32 | 37 | N/A |
| 3/31/2020 | 18 | -115 | -110 | -109 | N/A |
| 12/31/2019 | 19 | -133 | -138 | -137 | N/A |
| 9/30/2019 | 16 | -150 | -160 | -158 | N/A |
| 6/30/2019 | 21 | -177 | -162 | -159 | N/A |
| 3/31/2019 | 29 | -182 | -171 | -169 | N/A |
| 12/31/2018 | 34 | -185 | -186 | -185 | N/A |
| 9/30/2018 | 39 | -186 | -184 | -183 | N/A |
| 6/30/2018 | 39 | -186 | -196 | -194 | N/A |
| 3/31/2018 | 35 | -186 | N/A | -166 | N/A |
| 12/31/2017 | 31 | -184 | N/A | -144 | N/A |
| 9/30/2017 | 26 | -190 | N/A | -162 | N/A |
| 6/30/2017 | 21 | -212 | N/A | -181 | N/A |
| 3/31/2017 | 17 | -247 | N/A | -230 | N/A |
| 12/31/2016 | 15 | -280 | N/A | -259 | N/A |
| 9/30/2016 | 16 | -302 | N/A | -249 | N/A |
| 6/30/2016 | 19 | -269 | N/A | -215 | N/A |
| 3/31/2016 | 31 | -210 | N/A | -165 | N/A |
| 12/31/2015 | 36 | -157 | N/A | -126 | N/A |
| 9/30/2015 | 37 | -110 | N/A | -91 | N/A |
| 6/30/2015 | 39 | -96 | N/A | -78 | N/A |
| 3/31/2015 | 33 | -94 | N/A | -77 | N/A |
| 12/31/2014 | 31 | -83 | N/A | -67 | N/A |
| 9/30/2014 | 33 | -65 | N/A | -60 | N/A |
| 6/30/2014 | 29 | -61 | N/A | -59 | N/A |
| 3/31/2014 | 25 | -56 | N/A | -55 | N/A |
| 12/31/2013 | 21 | -52 | N/A | -45 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: NVAX is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (1.2%).
Earnings vs Market: NVAX is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: NVAX is expected to become profitable in the next 3 years.
Revenue vs Market: NVAX's revenue is expected to decline over the next 3 years (-14.6% per year).
High Growth Revenue: NVAX's revenue is forecast to decline over the next 3 years (-14.6% per year).
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if NVAX's Return on Equity is forecast to be high in 3 years time